Healthcare Specialties Driving M&A Activity: What Owners and Investors Should Know
Healthcare consolidation continues to reshape how specialty practices operate, compete, and deliver care. But not all specialties are attracting the same level of buyer interest — and understanding what’s driving deal flow in specific verticals matters whether you’re a practice owner weighing your options, a health system evaluating partnerships, or an investor building a platform thesis.
At The Bloom Organization, we advise healthcare business owners through sell-side M&A transactions. The patterns we see at the deal table — what buyers are pursuing, where multiples are holding, and which practice characteristics create competitive processes — inform how we help our clients prepare and position for a transaction.
Here’s where we’re seeing the most sustained buyer activity, and why.
Specialties Driving M&A Activity
Orthopedics and Musculoskeletal Care
Orthopedics has been one of the more active consolidation verticals for several years, and buyer interest hasn’t slowed. The thesis is straightforward: aging demographics drive consistent procedural volume, and the shift from inpatient to ambulatory surgery center (ASC) settings has created margin structures that attract both private equity and strategic buyers.
That said, not every orthopedic practice is equally positioned. Buyers are increasingly selective. Practices that have already made the transition to outpatient delivery — and that have diversified beyond surgical volume into rehabilitation, imaging, and interventional pain — tend to generate stronger buyer interest. Single-surgeon practices without ancillary revenue or ASC ownership face a different market.
Payor mix matters here too. Practices with heavy workers’ compensation exposure or a high percentage of personal injury cases may see different valuation dynamics than those with commercial-dominant panels.
Behavioral Health
Behavioral health deal activity has surged — driven by genuine demand-supply imbalance, expanded insurance parity, and growing employer investment in mental health benefits. The challenge for buyers isn’t finding demand. It’s finding platforms with the clinical infrastructure, credentialing depth, and provider retention to scale sustainably.
Buyers pay close attention to provider turnover, the mix between licensed therapists and prescribers, and whether a practice has built repeatable intake and care pathways or is still running on individual clinician relationships. Telebehavioral health capabilities have moved from differentiator to baseline expectation.
Substance use disorder (SUD) treatment sits adjacent but carries its own regulatory and reimbursement complexity. Practices operating across the SUD continuum — from outpatient counseling through intensive outpatient and residential — attract interest, but buyers will scrutinize state licensing, accreditation, and outcome measurement rigor.
Interventional Pain Management
Chronic pain prevalence and the ongoing shift away from opioid-centric treatment models have created a meaningful tailwind for interventional pain practices. Neuromodulation, regenerative medicine, and minimally invasive spinal procedures offer recurring patient relationships and favorable procedure economics.
What differentiates practices in this space from a buyer’s perspective is referral network strength and clinical documentation. Practices that can demonstrate measurable outcomes — reduced opioid utilization, functional improvement scores, return-to-work data — are better positioned in a market that increasingly ties reimbursement to value-based metrics.
Multidisciplinary models that integrate physical therapy and behavioral health alongside interventional procedures align well with where payors are heading, and buyers recognize that.
Gastroenterology
GI has become one of the most competitive consolidation verticals in healthcare. Endoscopy center ownership is the primary driver — practices with in-office or affiliated ASC-based endoscopy units generate procedure volume and ancillary revenue that make the economics compelling for platform buyers.
The colorectal cancer screening expansion (with the recommended screening age now starting at 45) has added a structural volume tailwind. Buyers are looking at scope: practices with integrated pathology, anesthesia, and imaging create tighter referral loops and capture more of the care dollar.
Physician alignment is a particular focus in GI transactions. Buyers want to understand governance structures, non-compete enforceability, and whether key physicians are committed to staying through and beyond a transition period. The concentration risk in smaller GI groups — where two or three physicians generate the majority of production — is a real diligence issue.
Dermatology
Dermatology consolidation has matured, but activity remains steady. The appeal is the dual revenue stream: insurance-based medical and surgical dermatology combined with cash-pay aesthetics. That diversification provides some insulation from reimbursement pressure on the medical side.
Buyers evaluate dermatology practices on a few key dimensions: the ratio of medical to cosmetic revenue, the degree of mid-level provider (PA/NP) leverage in the care model, geographic density, and whether the practice has built a recognizable consumer brand around its aesthetic offerings.
Practices that are heavily physician-dependent with limited mid-level integration may face questions about scalability. Those that have built efficient supervision models and standardized treatment protocols tend to be more attractive.
Women’s Health and Fertility
Women’s health platforms — particularly those with fertility service lines — have drawn significant investor interest. The fertility segment specifically benefits from rising utilization, expanding employer-sponsored benefits, and a patient population that tends to be commercially insured.
OB/GYN practices outside of fertility face a different dynamic. Reimbursement pressure on obstetric services and the malpractice cost environment create margin challenges that buyers factor into their models. Practices that have diversified into gynecologic surgery, hormone therapy, or wellness services beyond traditional OB tend to be better positioned.
In fertility, buyers are focused on clinical outcomes data (success rates by age cohort and procedure type), physician recruitment pipelines, and the ability to expand into new geographies without proportional increases in overhead.
What This Means If You’re Considering a Transaction
Buyer interest in a specialty vertical is a starting point, not a guarantee. The practices that attract competitive processes and favorable terms are typically the ones that have done the operational work: clean financials with normalized EBITDA that can withstand diligence scrutiny, documented clinical workflows, diversified payor relationships, and a leadership team prepared to articulate a credible growth story.
If you’re a healthcare business owner exploring whether now is the right time to go to market — or if you want to understand what a buyer would see when they look at your practice — that’s the conversation we have with clients every day.
About The Bloom Organization
The Bloom Organization is a healthcare-focused M&A advisory firm that represents practice owners and physician groups in sell-side transactions. We work with owners across high-growth specialties to evaluate strategic options, prepare for market, and manage competitive sale processes designed to identify the right partner — not just the highest bid.
If you’re thinking about a transaction and want to understand how your practice would be positioned in today’s market, we’d welcome that conversation.